Alexi Anne Wright MD MPH

Gynecologic Cancer, Hematologic Oncology

Associate Professor, Harvard Medical School Medical Oncologist, Dana-Farber Cancer Institute

450 Brookline AveBoston, MA 02215
Phone+1 617-632-2334
Fax+1 617-632-3479

Dr. Wright is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Wright's full profile Already have an account?

Education & Training

Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2006 - 2009
Mass General Brigham/Brigham and Women's HospitalResidency, Internal Medicine, 2003 - 2006
Perelman School of Medicine at the University of PennsylvaniaClass of 2003

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

CT State Medical License 2022 - 2026
MA State Medical License 2005 - 2026
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification Partners Longitudinal Medical Record, Partners Healthcare System, 2013-2015, 2017
CMS Meaningful Use Stage 1 Certification Partners Longitudinal Medical Record, Partners Healthcare System, 2013-2015, 2017
CMS Meaningful Use Stage 2 Certification OpTime Surgical 2014 Certified Module, Epic Systems Corporation, 2013-2015, 2017

Clinical Trials

Study of an Intervention to Improve Problem List Accuracy and Use
UNKNOWN
NA
The HOPE Trial and the SMART Study Start of enrollment: 2017 Apr 12
COMPLETED
NA
Stepping Into Survivorship: Harnessing Behavioral Economics to Improve Quality of Life in Ovarian Cancer Start of enrollment: 2018 Jul 20
COMPLETED
NA

Publications & Presentations

PubMed

Characteristics, Diagnosis, and Treatment of Aphasia in Patients With Brain Tumors: A Scoping Review.
Alexander Finnemore, Maria T Paulino, Paul J Miller, Amy J Maguire, Justin Vinh
Neurology. 2026-08-11
Cost-effectiveness of a bevacizumab biosimilar for the treatment of recurrent, platinum-sensitive ovarian cancer in the United States.
Claudia L Seguin, Andrew Eckel, David H Howard, Mary Linton B Peters, Alexi A Wright
Gynecologic Oncology. 2026-08-01
Maintenance therapy in gynecologic malignancies: Current and future state.
Page C Widick, Alexi A Wright, Joyce F Liu
Cancer. 2026-07-15

Press Mentions

F.D.A. Approves First at-Home Alternative to the Pap SmearMay 9th, 2025
Dana-Farber Experts Present Innovative Cancer Studies at the 2025 AACR Annual MeetingApril 26th, 2025
Dana-Farber Research Highlights Head and Neck, Breast, Lung, and Survivorship Studies at AACR Annual Meeting 2025April 25th, 2025

Grant Support

Variability in Opioid Prescribing Across the Cancer Care Continuum: A Multi-Level AnalysisDANA-FARBER CANCER INST2024–2029
Variability in Opioid Prescribing Across the Cancer Care Continuum: A Multi-Level AnalysisDANA-FARBER CANCER INST2024–2029
Randomized trial of REVITALIZE: A telehealth intervention to reduce fatigue interference among adults with advanced ovarian cancer on PARP inhibitorsDANA-FARBER CANCER INST2024–2029
BOLSTER: Strengthening Patient and Caregiver Supports in Advanced Gynecologic and Gastrointestinal Cancers - a Multi-Site Randomized Controlled TrialDANA-FARBER CANCER INST2023–2028